Literature DB >> 9755900

Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH.

U Gietz1, R Alder, P Langguth, T Arvinte, H P Merkle.   

Abstract

PURPOSE: To gain information on the chemical stability pattern and the kinetics of the degradation of recombinant hirudin variant HV1 (rHir), a thrombin-specific inhibitor protein of 65 amino acids, in aqueous solution as a function of pH.
METHODS: Stability of rHir was monitored at 50 degrees C in the framework of a classical pH-stability study in aqueous buffers pH 1-9.5. Two capillary electrophoresis (CE) protocols were used: one for the kinetics of succinimide formation at Asp53-Gly54 (C-terminal tail) and Asp33-Gly34 (loop section), the other for the kinetics of rHir degradation. To check for potential effects of conformational changes by thermal denaturation, circular dichroism (CD) measurements were performed between 25 and 80 degrees C.
RESULTS: Throughout the pH range studied no effect of thermal denaturation on rHir confirmation at 50 degrees C was observed. rHir was most stable at a neutral pH whereas, at slightly acidic pH, an intermediate stability plateau was found. Both, strongly acidic and alkaline conditions led to fast rHir degradation. Depending on the pH of degradation, rHir was found to degrade in various combinations of multiple parallel and sequential degradation patterns. Special focus was on succinimide formation at Asp53-Gly54 (C-terminal tail) and Asp33-Gly34 (loop) and on the potential of isoAsp formation in position 53 and 33.
CONCLUSIONS: Chemical rHir stability in the intermediate pH range depends strongly on succinimide formation. At slightly acidic conditions succinimides represent the major degradation product (up to 40%). Around neutral pH succinimides react further, presumably by isoAsp formation, and concentrations remain low. Relative preference of succinimide formation in the C-terminal tail domain versus the loop domain is explained by higher backbone flexibility in the tail.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755900     DOI: 10.1023/a:1011918108849

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

Review 1.  Recombinant hirudin: genetic engineering and structure analysis.

Authors:  W E Märki; H Grossenbacher; M G Grütter; M H Liersch; B Meyhack; J Heim
Journal:  Semin Thromb Hemost       Date:  1991-04       Impact factor: 4.180

2.  Tertiary structure is a principal determinant to protein deamidation.

Authors:  A A Kossiakoff
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

3.  Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: effects of the solvent dielectric.

Authors:  T V Brennan; S Clarke
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

Review 4.  The development of hirudin as an antithrombotic drug.

Authors:  F Markwardt
Journal:  Thromb Res       Date:  1994-04-01       Impact factor: 3.944

5.  The mechanisms of irreversible enzyme inactivation at 100C.

Authors:  T J Ahern; A M Klibanov
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

6.  Characterization, stability and refolding of recombinant hirudin.

Authors:  A Otto; R Seckler
Journal:  Eur J Biochem       Date:  1991-11-15

7.  Aqueous stability of human epidermal growth factor 1-48.

Authors:  R I Senderoff; S C Wootton; A M Boctor; T M Chen; A B Giordani; T N Julian; G W Radebaugh
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

8.  Characterization of a beta-Asp33 isoform of recombinant hirudin sequence variant 1 by low-energy collision-induced dissociation.

Authors:  P Schindler; D Müller; W Märki; H Grossenbacher; W J Richter
Journal:  J Mass Spectrom       Date:  1996-09       Impact factor: 1.982

9.  Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; R T Borchardt
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

10.  Separation of r-hirudin from similar substances by capillary electrophoresis.

Authors:  C Dette; H Wätzig
Journal:  J Chromatogr A       Date:  1995-05-12       Impact factor: 4.759

View more
  2 in total

1.  Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.

Authors:  Weiqiang Cheng; Elena Curti; Wanderson C Rezende; Clifford Kwityn; Bin Zhan; Portia Gillespie; Jordan Plieskatt; Sangeeta B Joshi; David B Volkin; Peter J Hotez; C Russell Middaugh; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

2.  Inhibition of succinimide formation in aqueous Zn-rHirudin suspensions.

Authors:  U Gietz; T Arvinte; R Alder; H P Merkle
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.